As researchers across
the globe race to develop a vaccine
to tackle the pandemic, Patanjali Ayurveda Limited, claimed
that his company developed an Ayurveda medicine that has cured Covid-19 patients
within a span of five to 14 days.
Acharya Balkrishna, co-founder and Chief Executive
Officer (CEO) of Patanjali said that a trial was conducted on hundreds of
Covid-19 patients and that the medicine has yielded 100% favourable results. “We appointed
a team of scientists after the Covid-19 outbreak. First, the simulation was
done and compounds were identified which can fight the virus and stop its
spread in the body. Then, we conducted a clinical case study on hundreds of
positive patients and we have got 100 per cent favourable results” Balkrishna
said in Haridwar.
“We
can say that the cure for COVID is possible through Ayurveda” he claimed,
adding that the company is now conducting controlled clinical trials and will
release evidence in less than a week.
More than 100 potential
Covid-19 vaccines are in various stages of development around the world. Among
front runners currently in human trials are the Covid-19 vaccines being
developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck,
Moderna, Sanofi and China’s CanSino Biologics.
World famous Yoga Guru Ramdev baba established
the Patanjali Ayurved Limited in 2006 along with Balkrishna, with the
objective of establishing science of Ayurveda in accordance and
coordination with the latest technology and ancient wisdom. Balkrishna owns
98.6% of Patanjali Ayurved, and as of March 2018, has a net worth of
₹43,932 crore (US$6.1 billion).
Patanjali Ayurved produces products in the
categories of personal care and food. The company manufactures more than
2,500 products including 45 types of cosmetic products and 30 types of food
products. According to Patanjali, all the products manufactured by Patanjali
are made from Ayurveda and natural components. Patanjali has
also launched beauty and baby products. Patanjali Ayurvedic manufacturing
division has over 300 medicines for treating a range of ailments and body
conditions, from common cold to chronic paralysis. In 2016,
Patanjali has announced to enter the textile manufacturing centre. On 5
November 2016, Patanjali announced that it will set up a new manufacturing
plant Patanjali Herbal and Mega Food Park in Balipara, Assam by investing ₹1,200
crore (US$170 million) with the manufacturing capacity of
10 lakh tonnes of goods per year. The new plant will be the
largest facility of Patanjali in India and will be operational by
March 2017. Patanjali already has around 50 manufacturing units
across India.
0 टिप्पणियाँ